{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T00:51:39Z","timestamp":1778892699580,"version":"3.51.4"},"reference-count":62,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Objective<\/jats:title>\n<jats:p>Risperidone, a second-generation antipsychotic widely used in clinical practice, has not been systematically evaluated for its long-term real-world adverse events. This study analyzed risperidone-related AEs reported in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) over nearly two decades, providing a reference for clinical medication.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>Data on risperidone was collected from FAERS covering the period from the first quarter of 2004 to the third quarter of 2024. Signal detection was performed using the reporting odds ratio, proportional reporting ratio, Bayesian confidence propagation neural network, and multi-item gamma Poisson shrinker algorithms.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>Among the 18,089 reports collected, a total of 27 system organ classes and 452 preferred terms were identified. Nervous system disorders, Psychiatric disorders, General disorders and administration site conditions, and Injury, poisoning and procedural complications were the primary SOCs. Additionally, Reproductive system and breast disorders, Endocrine disorders, Metabolism and nutrition disorders, and Cardiac disorders showed a strong association with risperidone, warranting heightened vigilance. This study identified a substantial number of extrapyramidal-related AEs, including propulsive gait, spasmodic dysphonia, tongue thrust, respiratory dyskinesia, oromandibular dystonia, cogwheel rigidity, and pleurothotonus. Rare cardiovascular events such as Wellens\u2019 syndrome and endocarditis fibroplastica were also uncovered through in-depth analysis. Furthermore, AEs like paroxysmal perceptual alteration, pulmonary vein occlusion, and floppy iris syndrome, although infrequent, exhibited high signal strength. This study also identified noteworthy signals not included in the risperidone label, such as rabbit syndrome (perioral tremor), jaw clicking, and portal vein cavernous transformation, which merit further investigation.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusion<\/jats:title>\n<jats:p>From the perspectives of physicians and pharmacists, this research provides a unique and robust theoretical foundation for evaluating the safety profile of risperidone and offers direction for future studies on its adverse events.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0331983","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T17:28:39Z","timestamp":1760722119000},"page":"e0331983","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":2,"title":["Real-world pharmacovigilance of risperidone: Analysis based on FAERS reports from physicians and pharmacists"],"prefix":"10.1371","volume":"20","author":[{"given":"Gang","family":"Hao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi","family":"Jia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Zan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaomin","family":"Lv","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Na","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4861-9851","authenticated-orcid":true,"given":"Junyin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2025,10,17]]},"reference":[{"issue":"1","key":"pone.0331983.ref001","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.MS21078COM5","article-title":"The Epidemiology and Global Burden of Schizophrenia","volume":"84","author":"DI Velligan","year":"2023","journal-title":"J Clin Psychiatry"},{"key":"pone.0331983.ref002","article-title":"Trends in the incidence and DALYs of schizophrenia at the global, regional and national levels: results from the Global Burden of Disease Study 2017","volume":"29","author":"H He","year":"2020","journal-title":"Epidemiol Psychiatr Sci"},{"issue":"12","key":"pone.0331983.ref003","doi-asserted-by":"crossref","first-page":"5319","DOI":"10.1038\/s41380-023-02138-4","article-title":"Incidence, prevalence, and global burden of schizophrenia - data, with critical appraisal, from the Global Burden of Disease (GBD) 2019","volume":"28","author":"M Solmi","year":"2023","journal-title":"Mol Psychiatry"},{"issue":"4","key":"pone.0331983.ref004","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S2215-0366(17)30078-0","article-title":"Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis","volume":"4","author":"C Hjorth\u00f8j","year":"2017","journal-title":"Lancet Psychiatry"},{"issue":"6","key":"pone.0331983.ref005","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.22m14458","article-title":"The Economic Burden of Schizophrenia in the United States","volume":"83","author":"A Kadakia","year":"2022","journal-title":"J Clin Psychiatry"},{"key":"pone.0331983.ref006","doi-asserted-by":"crossref","first-page":"110296","DOI":"10.1016\/j.cbi.2022.110296","article-title":"Neuropharmacological effect of risperidone: From chemistry to medicine","volume":"369","author":"AA Bhat","year":"2023","journal-title":"Chem Biol Interact"},{"issue":"9657","key":"pone.0331983.ref007","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)61764-X","article-title":"Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis","volume":"373","author":"S Leucht","year":"2009","journal-title":"Lancet"},{"issue":"8","key":"pone.0331983.ref008","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1017\/S0033291720003335","article-title":"A randomized controlled trial of cognitive remediation and long-acting injectable risperidone after a first episode of schizophrenia: improving cognition and work\/school functioning","volume":"52","author":"KH Nuechterlein","year":"2022","journal-title":"Psychol Med"},{"key":"pone.0331983.ref009","doi-asserted-by":"crossref","first-page":"112709","DOI":"10.1016\/j.ejmech.2020.112709","article-title":"Isoquinolinone derivatives as potent CNS multi-receptor D2\/5-HT1A\/5-HT2A\/5-HT6\/5-HT7 agents: Synthesis and pharmacological evaluation","volume":"207","author":"J Jin","year":"2020","journal-title":"Eur J Med Chem"},{"issue":"9","key":"pone.0331983.ref010","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.jaac.2023.03.007","article-title":"Antipsychotic-Related Prolactin Levels and Sexual Dysfunction in Mentally Ill Youth: A 3-Month Cohort Study","volume":"62","author":"MT Koch","year":"2023","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"7","key":"pone.0331983.ref011","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/S2215-0366(18)30141-X","article-title":"Antipsychotic treatment of very late-onset schizophrenia-like psychosis (ATLAS): a randomised, controlled, double-blind trial","volume":"5","author":"R Howard","year":"2018","journal-title":"Lancet Psychiatry"},{"key":"pone.0331983.ref012","doi-asserted-by":"crossref","first-page":"115637","DOI":"10.1016\/j.psychres.2023.115637","article-title":"Effectiveness and safety of second-generation antipsychotics for psychiatric disorders apart from schizophrenia: A systematic review and meta-analysis","volume":"332","author":"X-Z Feng","year":"2024","journal-title":"Psychiatry Res"},{"key":"pone.0331983.ref013","unstructured":"Healthy Canadians. Risperidone -Restriction of the Dementia Indication 2015. Available from: https:\/\/www.tga.gov.au\/sites\/default\/files\/foi-1139-13.pdf#:~:text=The%20indication%20for%20risperidone%20in%20dementia%20has%20been,a%20risk%20of%20harm%20to%20self%20or%20others"},{"issue":"2","key":"pone.0331983.ref014","article-title":"Hepatotoxicity to Risperidone","volume":"26","author":"RT Andr\u00e9","year":"2024","journal-title":"Prim Care Companion CNS Disord"},{"key":"pone.0331983.ref015","doi-asserted-by":"crossref","first-page":"1369384","DOI":"10.3389\/fphar.2024.1369384","article-title":"Safety assessment of cenobamate: real-world adverse event analysis from the FAERS database","volume":"15","author":"S Chen","year":"2024","journal-title":"Front Pharmacol"},{"issue":"1","key":"pone.0331983.ref016","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/pds.668","article-title":"A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions","volume":"11","author":"EP van Puijenbroek","year":"2002","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"2","key":"pone.0331983.ref017","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s40268-015-0092-x","article-title":"Comparative Pharmacology of Risperidone and Paliperidone","volume":"15","author":"M Corena-McLeod","year":"2015","journal-title":"Drugs R D"},{"issue":"1","key":"pone.0331983.ref018","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/s41398-022-02027-4","article-title":"Pharmacological treatment strategies for antipsychotic-induced hyperprolactinemia: a systematic review and network meta-analysis","volume":"12","author":"Z Lu","year":"2022","journal-title":"Transl Psychiatry"},{"key":"pone.0331983.ref019","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.neuropharm.2006.07.006","article-title":"Distinct endocrine effects of chronic haloperidol or risperidone administration in male rats","volume":"51","author":"E-JD Lin","year":"2006","journal-title":"Neuropharmacology"},{"issue":"1","key":"pone.0331983.ref020","doi-asserted-by":"crossref","first-page":"22","DOI":"10.25259\/NMJI_115_20","article-title":"Risperidone-induced anaemia","volume":"36","author":"S Chawath","year":"2023","journal-title":"Natl Med J India"},{"issue":"5","key":"pone.0331983.ref021","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1055\/s-2006-948327","article-title":"Gender-specific effects in the treatment of acute schizophrenia with risperidone","volume":"39","author":"TJ Raedler","year":"2006","journal-title":"Pharmacopsychiatry"},{"issue":"5","key":"pone.0331983.ref022","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1517\/14740338.2012.712109","article-title":"Drug-induced gynecomastia: an evidence-based review","volume":"11","author":"F Deepinder","year":"2012","journal-title":"Expert Opin Drug Saf"},{"key":"pone.0331983.ref023","doi-asserted-by":"crossref","first-page":"874705","DOI":"10.3389\/fpsyt.2022.874705","article-title":"Risperidone Induced Hyperprolactinemia: From Basic to Clinical Studies","volume":"13","author":"M Stojkovic","year":"2022","journal-title":"Front Psychiatry"},{"key":"pone.0331983.ref024","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.pnpbp.2017.03.009","article-title":"The central mechanism of risperidone-induced hyperprolactinemia","volume":"76","author":"W-W Sun","year":"2017","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"9","key":"pone.0331983.ref025","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.4088\/JCP.08m04307yel","article-title":"Positron emission tomography measurement of dopamine D\u2082 receptor occupancy in the pituitary and cerebral cortex: relation to antipsychotic-induced hyperprolactinemia","volume":"71","author":"R Arakawa","year":"2010","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"pone.0331983.ref026","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/00004714-200204000-00002","article-title":"The effects of antipsychotic-induced hyperprolactinaemia on the hypothalamic-pituitary-gonadal axis","volume":"22","author":"S Smith","year":"2002","journal-title":"J Clin Psychopharmacol"},{"key":"pone.0331983.ref027","article-title":"Association between gonadal hormones and osteoporosis in schizophrenia patients undergoing risperidone monotherapy: a cross-sectional study","volume":"9","author":"Y Chen","year":"2021","journal-title":"PeerJ"},{"issue":"10","key":"pone.0331983.ref028","first-page":"1145","article-title":"Changes in serum thyroid hormone levels in psychiatric patients after risperidone monotherapy or polytherapy treatment","volume":"25","author":"D Shun-Shun","year":"2020","journal-title":"Chinese Journal of Clinical Pharmacology and Therapeutics"},{"key":"pone.0331983.ref029","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/s12888-014-0279-7","article-title":"Thyroid axis function after in-patient treatment of acute psychosis with antipsychotics: a naturalistic study","volume":"14","author":"R Bunevicius","year":"2014","journal-title":"BMC Psychiatry"},{"key":"pone.0331983.ref030","doi-asserted-by":"crossref","first-page":"569147","DOI":"10.1155\/2012\/569147","article-title":"Revisiting thyroid hormones in schizophrenia","volume":"2012","author":"NC Santos","year":"2012","journal-title":"J Thyroid Res"},{"issue":"5","key":"pone.0331983.ref031","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/cns.13281","article-title":"Risperidone stimulates food intake and induces body weight gain via the hypothalamic arcuate nucleus 5-HT2c receptor-NPY pathway","volume":"26","author":"X-Q Wan","year":"2020","journal-title":"CNS Neurosci Ther"},{"key":"pone.0331983.ref032","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2174\/1874205X01307010023","article-title":"Antipsychotic drugs opposite to metabolic risk: neurotransmitters, neurohormonal and pharmacogenetic mechanisms underlying with weight gain and metabolic syndrome","volume":"7","author":"W Milano","year":"2013","journal-title":"Open Neurol J"},{"issue":"7","key":"pone.0331983.ref033","article-title":"The atypical antipsychotic risperidone targets hypothalamic melanocortin 4 receptors to cause weight gain","volume":"218","author":"L Li","year":"2021","journal-title":"J Exp Med"},{"issue":"1","key":"pone.0331983.ref034","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1440-1819.2007.01610.x","article-title":"Glucose and lipid metabolism of long-term risperidone monotherapy in patients with schizophrenia","volume":"61","author":"M Murashita","year":"2007","journal-title":"Psychiatry Clin Neurosci"},{"issue":"8","key":"pone.0331983.ref035","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1038\/sj.npp.1300756","article-title":"Cortisol and cytokines in chronic and treatment-resistant patients with schizophrenia: association with psychopathology and response to antipsychotics","volume":"30","author":"XY Zhang","year":"2005","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"pone.0331983.ref036","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1097\/JCP.0000000000001318","article-title":"Comparison of the Metabolic Characteristics of Newer Second Generation Antipsychotics: Brexpiprazole, Lurasidone, Asenapine, Cariprazine, and Iloperidone With Olanzapine as a Comparator","volume":"41","author":"J Greger","year":"2021","journal-title":"J Clin Psychopharmacol"},{"issue":"1","key":"pone.0331983.ref037","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1186\/s12877-024-05371-w","article-title":"Serotonin syndrome caused by escitalopram in Parkinson\u2019s disease psychosis: a case report","volume":"24","author":"S Wang","year":"2024","journal-title":"BMC Geriatr"},{"key":"pone.0331983.ref038","doi-asserted-by":"crossref","first-page":"1257984","DOI":"10.3389\/fpsyt.2023.1257984","article-title":"Serotonin syndrome caused by a CYP2C19-mediated interaction between low-dose escitalopram and clopidogrel: a case report","volume":"14","author":"J Wu","year":"2023","journal-title":"Front Psychiatry"},{"issue":"12","key":"pone.0331983.ref039","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMicm2201699","article-title":"Wellens\u2019 Syndrome","volume":"387","author":"S Honda","year":"2022","journal-title":"N Engl J Med"},{"issue":"10","key":"pone.0331983.ref040","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1007\/s00210-016-1274-y","article-title":"Severe proarrhythmic potential of risperidone compared to quetiapine in an experimental whole-heart model of proarrhythmia","volume":"389","author":"G Frommeyer","year":"2016","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"2","key":"pone.0331983.ref041","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1177\/0269881104042618","article-title":"QTc interval, CYP2D6 and CYP2C9 genotypes and risperidone plasma concentrations","volume":"18","author":"A Llerena","year":"2004","journal-title":"J Psychopharmacol"},{"key":"pone.0331983.ref042","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.pnpbp.2013.10.020","article-title":"ECG parameters in children and adolescents treated with aripiprazole and risperidone","volume":"51","author":"E German\u00f2","year":"2014","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"1","key":"pone.0331983.ref043","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2018-227464","article-title":"Pseudo-Wellens\u2019 syndrome in pulmonary embolism","volume":"11","author":"YR Sedhai","year":"2018","journal-title":"BMJ Case Rep"},{"key":"pone.0331983.ref044","volume-title":"Psychopathology of schizophrenia","author":"N Yamaguchi","year":"1985"},{"issue":"5","key":"pone.0331983.ref045","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1097\/01.jcp.0000088910.24613.44","article-title":"Recurrent episodes of perceptual alteration in patients treated with antipsychotic agents","volume":"23","author":"H Uchida","year":"2003","journal-title":"J Clin Psychopharmacol"},{"issue":"2","key":"pone.0331983.ref046","first-page":"127","article-title":"Paroxysmal perceptual alteration in comparison with hallucination--a review of its clinical reports and discussion of its pathophysiological mechanism in the present day, when second generation antipsychotics are widely used","volume":"111","author":"K Watanabe","year":"2009","journal-title":"Seishin Shinkeigaku Zasshi"},{"issue":"6","key":"pone.0331983.ref047","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1089\/cap.2012.0053","article-title":"Risperidone-induced paroxysmal perceptual alteration in a child with autism","volume":"22","author":"H Bozkurt","year":"2012","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"12","key":"pone.0331983.ref048","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1176\/appi.ajp.160.12.2243-a","article-title":"Antipsychotic-induced paroxysmal perceptual alteration","volume":"160","author":"H Uchida","year":"2003","journal-title":"Am J Psychiatry"},{"issue":"3","key":"pone.0331983.ref049","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/j.1440-1819.2009.01963.x","article-title":"Antipsychotic-induced paroxysmal perceptual alteration in a patient with major depressive disorder","volume":"63","author":"P Pariwatcharakul","year":"2009","journal-title":"Psychiatry Clin Neurosci"},{"issue":"6","key":"pone.0331983.ref050","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/j.pnpbp.2010.06.001","article-title":"Clozapine-induced persistent paroxysmal perceptual alteration","volume":"34","author":"SK Praharaj","year":"2010","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"6","key":"pone.0331983.ref051","doi-asserted-by":"crossref","DOI":"10.1097\/MJT.0000000000001308","article-title":"Probable Lithium-Related Paroxysmal Perceptual Alterations in an Adolescent With Bipolar Mood Disorder","volume":"28","author":"A Naguy","year":"2020","journal-title":"Am J Ther"},{"issue":"1","key":"pone.0331983.ref052","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1186\/s12888-023-05379-3","article-title":"Oculogyric crisis symptoms related to risperidone treatment: a case report","volume":"23","author":"T Lv","year":"2023","journal-title":"BMC Psychiatry"},{"issue":"5","key":"pone.0331983.ref053","doi-asserted-by":"crossref","first-page":"769","DOI":"10.4088\/JCP.08l04572","article-title":"Lupus anticoagulant and anticardiolipin antibodies in serum of patients treated with risperidone","volume":"70","author":"M Schwartz","year":"2009","journal-title":"J Clin Psychiatry"},{"key":"pone.0331983.ref054","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14740338.2024.2396390","article-title":"Association between antipsychotics and pulmonary embolism: a pharmacovigilance analysis","author":"J Huang","year":"2024","journal-title":"Expert Opin Drug Saf"},{"issue":"4","key":"pone.0331983.ref055","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.jcjo.2016.02.008","article-title":"Intraoperative floppy-iris syndrome associated with use of antipsychotic drugs","volume":"51","author":"M Matsuo","year":"2016","journal-title":"Can J Ophthalmol"},{"issue":"4","key":"pone.0331983.ref056","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2165\/00023210-200418040-00002","article-title":"Antipsychotic-induced rabbit syndrome: epidemiology, management and pathophysiology","volume":"18","author":"M Schwartz","year":"2004","journal-title":"CNS Drugs"},{"issue":"6","key":"pone.0331983.ref057","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1176\/ajp.129.6.765","article-title":"Tardive dyskinesia and the rabbit syndrome during wakefulness and sleep","volume":"129","author":"K Jus","year":"1972","journal-title":"Am J Psychiatry"},{"issue":"3","key":"pone.0331983.ref058","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1159\/000118825","article-title":"The rabbit syndrome and antiparkinsonian medication in schizophrenic patients","volume":"25","author":"Y Wada","year":"1992","journal-title":"Neuropsychobiology"},{"issue":"8","key":"pone.0331983.ref059","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.3390\/medicina60081347","article-title":"A Systematic Review of Oral Vertical Dyskinesia (\u201cRabbit\u201d Syndrome)","volume":"60","author":"JP Rissardo","year":"2024","journal-title":"Medicina (Kaunas)"},{"issue":"6","key":"pone.0331983.ref060","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/0030-4220(88)90005-9","article-title":"Long-term prognosis for the clicking jaw","volume":"65","author":"RI Brooke","year":"1988","journal-title":"Oral Surg Oral Med Oral Pathol"},{"issue":"1","key":"pone.0331983.ref061","first-page":"52","article-title":"Temporomandibular Disorders: Rapid Evidence Review","volume":"107","author":"EM Matheson","year":"2023","journal-title":"Am Fam Physician"},{"issue":"2","key":"pone.0331983.ref062","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1080\/08869634.2001.11746161","article-title":"Emotional stress and craniomandibular dysfunction in children","volume":"19","author":"AP Vanderas","year":"2001","journal-title":"Cranio"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0331983","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T17:28:47Z","timestamp":1760722127000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0331983"}},"subtitle":[],"editor":[{"given":"Souparno","family":"Mitra","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2025,10,17]]},"references-count":62,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10,17]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0331983","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,17]]}}}